The role of receptor structure in determining adenosine receptor activity.

Abstract:

:Adenosine produces a wide variety of physiological effects through the activation of cell surface adenosine receptors (ARs). ARs are members of the G-protein-coupled receptor family, and currently, four subtypes, the A1AR, A2AAR, A2BAR, and A3AR, are recognized. This review focuses on the role of receptor structure in governing various facets of AR activity. Ligand-binding properties of ARs are primarily dictated by amino acids in the transmembrane domains of the receptors, although a role for extracellular domains of certain ARs has been suggested. Studies have identified certain amino acids conserved amongst AR subtypes that are critical for ligand recognition, as well as additional residues that may differentiate between agonist and antagonist ligands. Receptor regions responsible for activation of Gs have been identified for the A2AAR. The location of these intracellular sites is consistent with findings described for other G-protein-coupled receptors. Site-directed mutagenesis has been employed to analyze the structural basis for the differences in the kinetics of the desensitization response displayed by various AR subtypes. For the A2AAR and A3AR, agonist-stimulated phosphorylation of the AR, presumably via a G-protein receptor kinase, has been shown to occur. For these AR subtypes, intracellular regions or individual amino acids that may be targets for this phosphorylation have been identified. Finally, the role of A1AR gene structure in regulating the expression of this AR subtype is reviewed.

journal_name

Pharmacol Ther

authors

Olah ME,Stiles GL

doi

10.1016/s0163-7258(99)00051-0

subject

Has Abstract

pub_date

2000-02-01 00:00:00

pages

55-75

issue

2

eissn

0163-7258

issn

1879-016X

pii

S0163-7258(99)00051-0

journal_volume

85

pub_type

杂志文章,评审
  • Allosteric pathways in nuclear receptors - Potential targets for drug design.

    abstract::The nuclear receptor family of transcription factor proteins mediates endocrine function and plays critical roles in the development, physiology and pharmacology. Malfunctioning nuclear receptors are associated with several disease states. The functional activity of nuclear receptors is regulated by small molecular ho...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2017.10.014

    authors: Fernandez EJ

    更新日期:2018-03-01 00:00:00

  • Possibility of a rebound phenomenon following antiplatelet therapy withdrawal: a look at the clinical and pharmacological evidence.

    abstract::The importance of regular administration of antiplatelet drugs in patients suffering from coronary artery disease stands on firm grounds, as large meta-analyses have shown these therapies to drastically reduce the risk of death. Although the current guidelines published jointly by the American Heart Association, the A...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2009.03.019

    authors: Lordkipanidzé M,Diodati JG,Pharand C

    更新日期:2009-08-01 00:00:00

  • Comparative effects of DHA and EPA on cell function.

    abstract::Fish oil supplementation has been reported to be generally beneficial in autoimmune, inflammatory and cardiovascular disorders. Most researchers have attributed these beneficial effects to the high content of omega-3 fatty acids in fish oil (FO). The effects of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2009.01.004

    authors: Gorjão R,Azevedo-Martins AK,Rodrigues HG,Abdulkader F,Arcisio-Miranda M,Procopio J,Curi R

    更新日期:2009-04-01 00:00:00

  • Purinergic P2Y receptors: Molecular diversity and implications for treatment of cardiovascular diseases.

    abstract::Purinergic signaling, mediated mainly by G protein-coupled P2Y receptors (P2YRs), is now attracting attention as a new therapeutic target for preventing or treating cardiovascular diseases. Observations using mice with genetically modified P2YRs and/or treated with a pharmacological P2YR inhibitor have helped us under...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2017.06.010

    authors: Nishimura A,Sunggip C,Oda S,Numaga-Tomita T,Tsuda M,Nishida M

    更新日期:2017-12-01 00:00:00

  • Analysis of natural product regulation of cannabinoid receptors in the treatment of human disease.

    abstract::The organized, tightly regulated signaling relays engaged by the cannabinoid receptors (CBs) and their ligands, G proteins and other effectors, together constitute the endocannabinoid system (ECS). This system governs many biological functions including cell proliferation, regulation of ion transport and neuronal mess...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2017.06.003

    authors: Badal S,Smith KN,Rajnarayanan R

    更新日期:2017-12-01 00:00:00

  • Renal dopamine receptors in health and hypertension.

    abstract::During the past decade, it has become evident that dopamine plays an important role in the regulation of renal function and blood pressure. Dopamine exerts its actions via a class of cell-surface receptors coupled to G-proteins that belong to the rhodopsin family. Dopamine receptors have been classified into two famil...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/s0163-7258(98)00027-8

    authors: Jose PA,Eisner GM,Felder RA

    更新日期:1998-11-01 00:00:00

  • Oncogenic pathways that affect antitumor immune response and immune checkpoint blockade therapy.

    abstract::Mechanistic insights of cancer immunology have led to the development of immune checkpoint blockade therapy (ICBT), which has elicited a remarkable clinical response in some cancer patients. Increasing evidence suggests that activation of oncogenic pathways, such as RAS/RAF/MAPK and PI3K signaling, impairs the antitum...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2017.07.004

    authors: Zhao X,Subramanian S

    更新日期:2018-01-01 00:00:00

  • Emerging bronchoscopic treatments for chronic obstructive pulmonary disease.

    abstract::Chronic obstructive pulmonary disease (COPD) is a progressive lung disease characterized by pathophysiological factors including airflow limitation, hyperinflation and reduced gas exchange. Treatment consists of lifestyle changes, lung rehabilitation and pharmacological therapies such as long acting beta-2-agonists (L...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2017.05.007

    authors: van Geffen WH,Kerstjens HAM,Slebos DJ

    更新日期:2017-11-01 00:00:00

  • Crosstalk between mitogen-activated protein kinases and mitochondria in cardiac diseases: therapeutic perspectives.

    abstract::Cardiovascular diseases cause more mortality and morbidity worldwide than any other diseases. Although many intracellular signaling pathways influence cardiac physiology and pathology, the mitogen-activated protein kinase (MAPK) family has garnered significant attention because of its vast implications in signaling an...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2014.05.013

    authors: Javadov S,Jang S,Agostini B

    更新日期:2014-11-01 00:00:00

  • Getting to the heart of asthma: can "beta blockers" be useful to treat asthma?

    abstract::beta(2)-adrenoceptor agonists are the mainstay for the acute symptomatic treatment of asthma and provide effective bronchoprotection to a wide range of bronchoconstrictor agents. However, over the past 4 decades there has been a continuing debate concerning whether regular chronic treatment with these drugs may be doi...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2007.04.009

    authors: Bond RA,Spina D,Parra S,Page CP

    更新日期:2007-09-01 00:00:00

  • Estradiol effects on hypothalamic AMPK and BAT thermogenesis: A gateway for obesity treatment?

    abstract::In addition to their prominent roles in the control of reproduction, estrogens are important modulators of energy balance, as evident in conditions of deficiency of estrogens, which are characterized by increased feeding and decreased energy expenditure, leading to obesity. AMP-activated protein kinase (AMPK) is a ubi...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2017.03.014

    authors: López M,Tena-Sempere M

    更新日期:2017-10-01 00:00:00

  • The poly(I:C)-induced maternal immune activation model in preclinical neuropsychiatric drug discovery.

    abstract::Increasing epidemiological and experimental evidence implicates gestational infections as one important factor involved in the pathogenesis of several neuropsychiatric disorders. Corresponding preclinical model systems based upon maternal immune activation (MIA) by treatment of the pregnant female have been developed....

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2015.01.001

    authors: Reisinger S,Khan D,Kong E,Berger A,Pollak A,Pollak DD

    更新日期:2015-05-01 00:00:00

  • The role of the leukemia inhibitory factor receptor in neuroprotective signaling.

    abstract::Several neurotropic cytokines relay their signaling through the leukemia inhibitory factor receptor. This 190kDa subunit couples with the 130kDa gp130 subunit to transduce intracellular signaling in neurons and oligodendrocytes that leads to expression of genes associated with neurosurvival. Moreover, activation of th...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2017.08.008

    authors: Davis SM,Pennypacker KR

    更新日期:2018-03-01 00:00:00

  • Cytokine gene-modified vaccines in the therapy of cancer.

    abstract::Therapeutic strategies based on the insertion of cytokine genes into the genome of tumour cells, followed by vaccination with the resulting genetically modified, cytokine-producing cells, represent a new potential prospect for treatment of cancer patients. In this review, the concept of cytokine gene-modified cancer v...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/0163-7258(95)02016-0

    authors: Bubenik J

    更新日期:1996-01-01 00:00:00

  • Does Thiazolidinedione therapy exacerbate fluid retention in congestive heart failure?

    abstract::The ever-growing global burden of congestive heart failure (CHF) and type 2 diabetes mellitus (T2DM) as well as their co-existence necessitate that anti-diabetic pharmacotherapy will modulate the cardiovascular risk inherent to T2DM while complying with the accompanying restrictions imposed by CHF. The thiazolidinedio...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2016.09.007

    authors: Goltsman I,Khoury EE,Winaver J,Abassi Z

    更新日期:2016-12-01 00:00:00

  • PARP inhibition in the ovarian cancer patient: Current approvals and future directions.

    abstract::Poly (ADP-ribose) polymerase (PARP) inhibitors have transformed the therapeutic management of solid tumors, particularly ovarian cancer. Initially studied in BRCA deficient tumors, the Food and Drug Administration (FDA) indications have expanded to include other homologous recombination deficient tumors as well as bio...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2020.107588

    authors: Kurnit KC,Avila M,Hinchcliff EM,Coleman RL,Westin SN

    更新日期:2020-09-01 00:00:00

  • Intestinal microbiome as a novel therapeutic target for local and systemic inflammation.

    abstract::Recently, the pathogenesis of systemic inflammatory disease such as inflammatory bowel disease (IBD), multiple sclerosis (MS), systemic inflammatory arthritis, asthma, and non-alcoholic fatty liver disease has been reported to be related to the dysbiosis of gut microbiota. The contribution of special bacteria for the ...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2019.03.006

    authors: Uchiyama K,Naito Y,Takagi T

    更新日期:2019-07-01 00:00:00

  • Primaquine pharmacology in the context of CYP 2D6 pharmacogenomics: Current state of the art.

    abstract::Primaquine is the only antimalarial drug available to clinicians for the treatment of relapsing forms of malaria. Primaquine development and usage dates back to the 1940s and has been administered to millions of individuals to treat and eliminate malaria infections. Primaquine therapy is not without disadvantages, how...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2016.03.011

    authors: Marcsisin SR,Reichard G,Pybus BS

    更新日期:2016-05-01 00:00:00

  • Early clinical development: evaluation of drug-induced torsades de pointes risk.

    abstract::Drug-induced arrhythmias or QT interval prolongation is one of the two most common reasons for drugs to be denied regulatory approval or to have warnings imposed on their clinical labelling. The assessment of torsades de pointes (TdP) risk during clinical development of a new pharmaceutical compound has been an issue ...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1016/j.pharmthera.2008.05.006

    authors: Vik T,Pollard C,Sager P

    更新日期:2008-08-01 00:00:00

  • Anti-oxidative, anti-cancer and anti-inflammatory actions by thioredoxin 1 and thioredoxin-binding protein-2.

    abstract::Thioredoxin 1 (Trx 1) is a 12-kDa protein with redox-active dithiol in the active site -Cys-Gly-Pro-Cys- that is ubiquitously present in the human body. Trx 1 is a defensive protein induced by various stresses and has anti-oxidative, anti-apoptotic and anti-inflammatory effects. The anti-oxidative effect of Trx 1 is m...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2010.04.004

    authors: Watanabe R,Nakamura H,Masutani H,Yodoi J

    更新日期:2010-09-01 00:00:00

  • Therapeutic applications of ribozymes.

    abstract::The demonstration that RNA can be cleaved by cis or trans ribozymes (catalytic RNAs, RNA enzymes) has potentially important therapeutic implications. Since their discovery in the 1980s, the biochemistry and conserved sequences of ribozymes have been well characterized. Ribozymes are effective modulators of gene expres...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/0163-7258(95)02008-x

    authors: Kijima H,Ishida H,Ohkawa T,Kashani-Sabet M,Scanlon KJ

    更新日期:1995-01-01 00:00:00

  • Therapy of pulmonary hypertension in neonates and infants.

    abstract::Pulmonary hypertension (PH) in newborns and infants can present in its idiopathic form or complicate a long list of other diseases. Most of these conditions are either pulmonary or cardiovascular in origin. In the present review our current knowledge regarding pathophysiology, structural changes, diagnosis, and availa...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2007.03.006

    authors: Hoehn T

    更新日期:2007-06-01 00:00:00

  • In utero drug therapy.

    abstract::Drug therapy directed toward the fetus would be intended for either treating a fetal disorder or improving the capacity for later intrauterine or postnatal adaptation. Most reported trials involve single cases or small numbers of fetuses receiving the drug transplacentally after the first trimester, but before attaini...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/0163-7258(93)90051-e

    authors: Rayburn WF,Payne GG Jr

    更新日期:1993-01-01 00:00:00

  • TGF-β/BMP proteins as therapeutic targets in renal fibrosis. Where have we arrived after 25 years of trials and tribulations?

    abstract::The understanding of renal fibrosis in chronic kidney disease (CKD) remains as a challenge. More than 10% of the population of developed countries suffer from CKD. Proliferation and activation of myofibroblasts and accumulation of extracellular matrix proteins are the main features of kidney fibrosis, a process in whi...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2015.10.003

    authors: Muñoz-Félix JM,González-Núñez M,Martínez-Salgado C,López-Novoa JM

    更新日期:2015-12-01 00:00:00

  • Ethanol-BDNF interactions: still more questions than answers.

    abstract::Brain-derived neurotrophic factor (BDNF) has emerged as a regulator of development, plasticity and, recently, addiction. Decreased neurotrophic activity may be involved in ethanol-induced neurodegeneration in the adult brain and in the etiology of alcohol-related neurodevelopmental disorders. This can occur through de...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2008.01.003

    authors: Davis MI

    更新日期:2008-04-01 00:00:00

  • Favipiravir, an anti-influenza drug against life-threatening RNA virus infections.

    abstract::Favipiravir has been developed as an anti-influenza drug and licensed as an anti-influenza drug in Japan. Additionally, favipiravir is being stockpiled for 2 million people as a countermeasure for novel influenza strains. This drug functions as a chain terminator at the site of incorporation of the viral RNA and reduc...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2020.107512

    authors: Shiraki K,Daikoku T

    更新日期:2020-05-01 00:00:00

  • A critical evaluation of in vitro cell culture models for high-throughput drug screening and toxicity.

    abstract::Drug candidate and toxicity screening processes currently rely on results from early-stage in vitro cell-based assays expected to faithfully represent essential aspects of in vivo pharmacology and toxicology. Several in vitro designs are optimized for high throughput to benefit screening efficiencies, allowing the ent...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2012.01.001

    authors: Astashkina A,Mann B,Grainger DW

    更新日期:2012-04-01 00:00:00

  • Metabolic polymorphisms.

    abstract::Polymorphisms have been detected in a variety of xenobiotic-metabolizing enzymes at both the phenotypic and genotypic level. In the case of four enzymes, the cytochrome P450 CYP2D6, glutathione S-transferase mu, N-acetyltransferase 2 and serum cholinesterase, the majority of mutations which give rise to a defective ph...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/0163-7258(93)90053-g

    authors: Daly AK,Cholerton S,Gregory W,Idle JR

    更新日期:1993-02-01 00:00:00

  • Binge-eating disorder: Clinical and therapeutic advances.

    abstract::Binge-eating disorder (BED) is the most prevalent eating disorder with estimates of 2-5% of the general adult population. Nonetheless, its pathophysiology is poorly understood. Furthermore, there exist few therapeutic options for its effective treatment. Here we review the current state of binge-eating neurobiology an...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2017.08.002

    authors: Hutson PH,Balodis IM,Potenza MN

    更新日期:2018-02-01 00:00:00

  • GABAA receptor pharmacology.

    abstract::gamma-Aminobutyric acid (GABA)A receptors for the inhibitory neurotransmitter GABA are likely to be found on most, if not all, neurons in the brain and spinal cord. They appear to be the most complicated of the superfamily of ligand-gated ion channels in terms of the large number of receptor subtypes and also the vari...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/0163-7258(95)02043-8

    authors: Johnston GA

    更新日期:1996-01-01 00:00:00